(AOF) – In the first quarter of 2022, the turnover of the Safe group amounted to 1.428 million euros, showing strong growth of 31%, despite a health crisis still present in the indirect markets. This quarterly turnover constitutes the second strongest quarterly commercial performance after the fourth quarter of 2019, which recorded a turnover of 1.502 million euros.
“The synergy of our Safe Orthopedics and Safe Medical entities is fully used for sustained innovation: The commercial deployments of Sycamore and Hickory will continue to accelerate French-German sales in the second quarter and should be available internationally from the second half The evaluation of SORA is proceeding in line with our expectations and the implementation of two new units is planned in France in the second quarter before being offered to the German and USA markets at the end of 2022”, commented Pierre Dumouchel, CEO and co-founder of Safe Orthopedics.
AOF – LEARN MORE
Boost for French pharmacy
At the end of a recent CSIS, the French authorities announced an amount of credits (7 billion euros) never reached: 1.5 billion for hospital-university research, 2 billion for investment in health via bpi france , 1.5 billion in aid for the relocation of industrial projects, and 2 billion to strengthen investment in three sectors of the future (bioproduction, digital medicine, and pandemic preparedness). In addition, the annual growth in drug expenditure reimbursed by Medicare will be 2.4%, which should generate growth of at least 0.5% in the turnover of laboratories,
Above all, the normal drug marketing procedure will be accelerated (up to 500 days saved) if the medical benefit rendered is sufficient.